The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•29 June 2026•

1 min read

Replimune Reports Q4 & FY2026 Results, Provides Business Update

Key Facts

1Replimune Group reported financial results for fiscal fourth quarter and year ended March 31, 2026, and provided a business update.

Replimune Group (REPL) reported its financial results for the fiscal fourth quarter and year ended March 31, 2026, and provided a business update, according to the press release. The announcement did not disclose specific revenue or loss figures, making it a routine update for investors.

The news comes after REPL stock closed at $11.63 on Friday, June 26, 2026, with the day's range between $9.88 and $11.73. Clinical-stage biotech stocks often experience sharp volatility around earnings dates, but this particular release lacked immediate catalysts beyond the operational update.

Sources: